FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104871844> ?p ?o ?g. }

• W2104871844 endingPage "2423" @default.
• W2104871844 startingPage "2417" @default.
• W2104871844 abstract "Arginine vasopressin may contribute to abnormalities in hemodynamics and fluid balance in heart failure through its actions on V(1A) (vascular and myocardial effects) and V(2) receptors (renal effects). Inhibiting the action of vasopressin may be beneficial in patients with heart failure.A total of 142 patients with symptomatic heart failure (New York Heart Association class III and IV) were randomized to double-blind, short-term treatment with conivaptan, a dual V(1a)/V(2) vasopressin receptor antagonist, at a single intravenous dose (10, 20, or 40 mg) or placebo. Compared with placebo, conivaptan at 20 and 40 mg significantly reduced pulmonary capillary wedge pressure (-2.6+/-0.7, -5.4+/-0.7, and -4.6+/-0.7 mm Hg for placebo and 20 and 40 mg groups, respectively; P<0.05) and right atrial pressure (-2.0+/-0.4, -3.7+/-0.4, and -3.5+/-0.4 mm Hg for placebo and 20 and 40 mg groups, respectively; P<0.05) during the 3- to 6-hour interval after intravenous administration. Conivaptan significantly increased urine output in a dose-dependent manner (-11+/-17, 68+/-17, 152+/-19, and 176+/-18 mL/hour for placebo and 10, 20, and 40 mg groups, respectively; P<0.001) during the first 4 hours after the dose. Changes in cardiac index, systemic and pulmonary vascular resistance, blood pressure, and heart rate did not significantly differ from placebo.In patients with advanced heart failure, vasopressin receptor antagonism with conivaptan resulted in favorable changes in hemodynamics and urine output without affecting blood pressure or heart rate. These data suggest that vasopressin is functionally significant in advanced heart failure and that further investigations are warranted to examine the effects of conivaptan on symptom relief and natural history in such patients." @default.
• W2104871844 created "2016-06-24" @default.
• W2104871844 creator A5010170432 @default.
• W2104871844 creator A5017806292 @default.
• W2104871844 creator A5020198299 @default.
• W2104871844 creator A5022908678 @default.
• W2104871844 creator A5028525301 @default.
• W2104871844 creator A5034442646 @default.
• W2104871844 creator A5046780897 @default.
• W2104871844 creator A5047753536 @default.
• W2104871844 creator A5051961415 @default.
• W2104871844 creator A5076758023 @default.
• W2104871844 creator A5080222829 @default.
• W2104871844 date "2001-11-13" @default.
• W2104871844 modified "2023-10-16" @default.
• W2104871844 title "Acute Hemodynamic Effects of Conivaptan, a Dual V _1A and V ₂ Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure" @default.
• W2104871844 cites W1501631919 @default.
• W2104871844 cites W1965995404 @default.
• W2104871844 cites W1968355808 @default.
• W2104871844 cites W1984193593 @default.
• W2104871844 cites W1994690457 @default.
• W2104871844 cites W2001341793 @default.
• W2104871844 cites W2011471736 @default.
• W2104871844 cites W2011628654 @default.
• W2104871844 cites W2012629707 @default.
• W2104871844 cites W2023846004 @default.
• W2104871844 cites W2025450939 @default.
• W2104871844 cites W2030725425 @default.
• W2104871844 cites W2032943519 @default.
• W2104871844 cites W2044033661 @default.
• W2104871844 cites W2428555817 @default.
• W2104871844 doi "https://doi.org/10.1161/hc4501.099313" @default.
• W2104871844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11705818" @default.
• W2104871844 hasPublicationYear "2001" @default.
• W2104871844 type Work @default.
• W2104871844 sameAs 2104871844 @default.
• W2104871844 citedByCount "346" @default.
• W2104871844 countsByYear W21048718442012 @default.
• W2104871844 countsByYear W21048718442013 @default.
• W2104871844 countsByYear W21048718442014 @default.
• W2104871844 countsByYear W21048718442015 @default.
• W2104871844 countsByYear W21048718442016 @default.
• W2104871844 countsByYear W21048718442017 @default.
• W2104871844 countsByYear W21048718442018 @default.
• W2104871844 countsByYear W21048718442019 @default.
• W2104871844 countsByYear W21048718442020 @default.
• W2104871844 countsByYear W21048718442021 @default.
• W2104871844 countsByYear W21048718442022 @default.
• W2104871844 countsByYear W21048718442023 @default.
• W2104871844 crossrefType "journal-article" @default.
• W2104871844 hasAuthorship W2104871844A5010170432 @default.
• W2104871844 hasAuthorship W2104871844A5017806292 @default.
• W2104871844 hasAuthorship W2104871844A5020198299 @default.
• W2104871844 hasAuthorship W2104871844A5022908678 @default.
• W2104871844 hasAuthorship W2104871844A5028525301 @default.
• W2104871844 hasAuthorship W2104871844A5034442646 @default.
• W2104871844 hasAuthorship W2104871844A5046780897 @default.
• W2104871844 hasAuthorship W2104871844A5047753536 @default.
• W2104871844 hasAuthorship W2104871844A5051961415 @default.
• W2104871844 hasAuthorship W2104871844A5076758023 @default.
• W2104871844 hasAuthorship W2104871844A5080222829 @default.
• W2104871844 hasBestOaLocation W21048718441 @default.
• W2104871844 hasConcept C126322002 @default.
• W2104871844 hasConcept C139940330 @default.
• W2104871844 hasConcept C142724271 @default.
• W2104871844 hasConcept C146556889 @default.
• W2104871844 hasConcept C164705383 @default.
• W2104871844 hasConcept C178853913 @default.
• W2104871844 hasConcept C204787440 @default.
• W2104871844 hasConcept C27081682 @default.
• W2104871844 hasConcept C2776370428 @default.
• W2104871844 hasConcept C2777953023 @default.
• W2104871844 hasConcept C2778198053 @default.
• W2104871844 hasConcept C31861589 @default.
• W2104871844 hasConcept C58245268 @default.
• W2104871844 hasConcept C71924100 @default.
• W2104871844 hasConcept C84393581 @default.
• W2104871844 hasConceptScore W2104871844C126322002 @default.
• W2104871844 hasConceptScore W2104871844C139940330 @default.
• W2104871844 hasConceptScore W2104871844C142724271 @default.
• W2104871844 hasConceptScore W2104871844C146556889 @default.
• W2104871844 hasConceptScore W2104871844C164705383 @default.
• W2104871844 hasConceptScore W2104871844C178853913 @default.
• W2104871844 hasConceptScore W2104871844C204787440 @default.
• W2104871844 hasConceptScore W2104871844C27081682 @default.
• W2104871844 hasConceptScore W2104871844C2776370428 @default.
• W2104871844 hasConceptScore W2104871844C2777953023 @default.
• W2104871844 hasConceptScore W2104871844C2778198053 @default.
• W2104871844 hasConceptScore W2104871844C31861589 @default.
• W2104871844 hasConceptScore W2104871844C58245268 @default.
• W2104871844 hasConceptScore W2104871844C71924100 @default.
• W2104871844 hasConceptScore W2104871844C84393581 @default.
• W2104871844 hasIssue "20" @default.
• W2104871844 hasLocation W21048718441 @default.
• W2104871844 hasLocation W21048718442 @default.
• W2104871844 hasOpenAccess W2104871844 @default.
• W2104871844 hasPrimaryLocation W21048718441 @default.
• W2104871844 hasRelatedWork W104098193 @default.

• next